martes, 7 de octubre de 2014

National Guideline Clearinghouse | Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.

full-text ►

National Guideline Clearinghouse | Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.



National Institute for Health and Care Excellence (NICE)

National Guideline Clearinghouse (NGC)

Guideline Title
Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.
Bibliographic Source(s)
National Institute for Health and Care Excellence (NICE). Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Jul. 59 p. (Technology appraisal guidance; no. 316). 
Guideline Status
This is the current release of the guideline.
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios:

Publicar un comentario